A Phase 1 interventional study of DAV132 and Moxifloxacin in Healthy, sponsored by Da Volterra. Completed at 1 site in France. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-28.
Sponsored by Da Volterra · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine whether DAV132 is safe and effective for capturing fecal residues of moxifloxacin in healthy volunteers.
The proposed study, DAV132-CL-1002, is to evaluate performances of DAV132 in healthy volunteers:
In addition, the security and acceptability of DAV132 used during 7 days will be evaluated.
The proposed study is prospective, randomized, controlled, four parallel groups, repeated doses, open-label study blinded to analytical and microbiological evaluations.
Da Volterra is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
must be either of non-child bearing potential (surgically sterilized at least 3 months prior to inclusion, or or having a negative pregnancy test and be not breastfeeding at screening, and using abstinence or a double method during the treatment period and for additional period of 2 weeks after the end of treatment.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Moxifloxacin, oral tablets, 400mg/day, once daily 5 days
Drug: Moxifloxacin
Moxifloxacin : 400mg/day for 5 days DAV132: 7.5g x3/day for 7 days
Device: DAV132 · Drug: Moxifloxacin
DAV132 oral, 7.5g x3/day for 7 days
Device: DAV132
Negative control: 7.5g x3/day for 7 days
Other: Negative Control
DAV132 is associated to moxifloxacin or it is evaluated alone
Moxifloxacin is used alone or associated to DAV132
Also known as: Avelox
Moxifloxacin is used alone
Moxifloxacin Fecal Pharmacokinetics: Area Under the Free Moxifloxacin Fecal Concentration-time Curve Over the Period Time From Beginning of Treatment to 16 Days After the Beginning of Treatment (AUC D1-D16)
Time frame: D1 pre-dose, D2, D3, D4, D5, D6, D7, D8, D9, D12, D16
Moxifloxacin Fecal Pharmacokinetics: Area Under the Free Moxifloxacin Fecal Concentration-time Curve Over the Period Time From Beginning of Treatment to 37 Days After the Beginning of Treatment (AUC D1-D37)
Time frame: D1 pre-dose, D2, D3, D4, D5, D6, D7, D8, D9, D12, D16, D23, D30, D37
Moxifloxacin Plasma Pharmacokinetics: AUC(0-24h) of Moxifloxacin Plasma Concentrations Over Time on D1
Time frame: D1: at pre-dose; 0h30; 1h; 1h30; 2h; 3h; 4h; 6h; 12h and 24h post-dose
Moxifloxacin Plasma Pharmacokinetics: AUC(0-24h) of Moxifloxacin Plasma Concentrations Over Time on D5
Time frame: D5: at pre-dose; 0h30; 1h; 1h30; 2h; 3h; 4h; 6h; 12h; 24h; 32h; 48h; 56h and 72h post-dose
Moxifloxacin Plasma Pharmacokinetics: Cmax of Moxifloxacin in Plasma on D1
Time frame: D1: at pre-dose; 0h30; 1h; 1h30; 2h; 3h; 4h; 6h; 12h and 24h post-dose
Moxifloxacin Plasma Pharmacokinetics: Cmax of Moxifloxacin in Plasma on D5
Time frame: D5: at pre-dose; 0h30; 1h; 1h30; 2h; 3h; 4h; 6h; 12h; 24h; 32h; 48h; 56h and 72h post-dose
Number of Adverse Events (Including Abnormal Laboratory Findings) Related to Study Product
Time frame: From randomization to 37 days after the beginning of treatment
Percentage of Subjects With Adverse Events Related to Study Product
Time frame: From randomization to 37 days after the beginning of treatment
Healthy volunteers were recruited from March 20th, 2014 (date of first enrolment) and October 17th, 2014 (date of last completed)
| Milestone | Moxifloxacin | DAV132 + Moxifloxacin | DAV132 | Negative Control |
|---|---|---|---|---|
| Started | 14 | 14 | 8 | 8 |
| Completed | 14 | 14 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
| μg/g.day | Moxifloxacin | Moxifloxacin + DAV132 |
|---|---|---|
| Moxifloxacin Fecal Pharmacokinetics: Area Under the Free Moxifloxacin Fecal Concentration-time Curve Over the Period Time From Beginning of Treatment to 16 Days After the Beginning of Treatment (AUC D1-D16) | 758.4 ± 359.3 | 8.28 ± 7.21 |
| μg/g.day | Moxifloxacin | Moxifloxacin + DAV132 |
|---|---|---|
| Moxifloxacin Fecal Pharmacokinetics: Area Under the Free Moxifloxacin Fecal Concentration-time Curve Over the Period Time From Beginning of Treatment to 37 Days After the Beginning of Treatment (AUC D1-D37) | 758.7 ± 359.5 | 8.74 ± 7.73 |
| µg/mL.h | Moxifloxacin | Moxifloxacin + DAV132 |
|---|---|---|
| Moxifloxacin Plasma Pharmacokinetics: AUC(0-24h) of Moxifloxacin Plasma Concentrations Over Time on D1 | 42.1 ± 7.01 | 41.9 ± 9.57 |
| µg/mL.h | Moxifloxacin | Moxifloxacin + DAV132 |
|---|---|---|
| Moxifloxacin Plasma Pharmacokinetics: AUC(0-24h) of Moxifloxacin Plasma Concentrations Over Time on D5 | 57.6 ± 13.83 | 50.5 ± 10.91 |
| µg/mL | Moxifloxacin | Moxifloxacin + DAV132 |
|---|---|---|
| Moxifloxacin Plasma Pharmacokinetics: Cmax of Moxifloxacin in Plasma on D1 | 4.02 ± 1.33 | 4.63 ± 0.97 |
| µg/mL | Moxifloxacin | Moxifloxacin + DAV132 |
|---|---|---|
| Moxifloxacin Plasma Pharmacokinetics: Cmax of Moxifloxacin in Plasma on D5 | 4.89 ± 1.21 | 4.60 ± 1.24 |
| events related to study product | Moxifloxacin | Moxifloxacin + DAV132 | DAV132 | Negative Control |
|---|---|---|---|---|
| Number of Adverse Events (Including Abnormal Laboratory Findings) Related to Study Product | 1 | 0 | 0 | 0 |
| % of subjects with at last 1 related AE | Moxifloxacin | Moxifloxacin + DAV132 | DAV132 | Negative Control |
|---|---|---|---|---|
| Percentage of Subjects With Adverse Events Related to Study Product | 7.14 | 0 | 0 | 0 |
Collected over Treatment period: - 5 days for Moxifloxacin group; - 7 days for the 3 other groups (DAV132 + Moxifloxacin, DAV132 and Negative Control groups). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Moxifloxacin | 0/14 (0%) | 0/14 (0%) | 6/14 (42.9%) |
| Moxifloxacin + DAV132 | 0/14 (0%) | 0/14 (0%) | 10/14 (71.4%) |
| DAV132 | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Negative Control | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Event | Moxifloxacin | Moxifloxacin + DAV132 | DAV132 | Negative Control |
|---|---|---|---|---|
| HeadacheNervous system disorders | 1/14 | 4/14 | 1/8 | 0/8 |
| FlatulenceGastrointestinal disorders | 0/14 | 2/14 | 0/8 | 0/8 |
| DiarrhoeaGastrointestinal disorders | 0/14 | 0/14 | 0/8 | 1/8 |
| Intestinal transit time abnormalInvestigations | 0/14 | 0/14 | 1/8 | 0/8 |
| DysmenorrhoeaReproductive system and breast disorders | 0/14 | 0/14 | 1/8 | 0/8 |
| Abdominal painGastrointestinal disorders | 1/14 | 1/14 | 0/8 | 0/8 |
| NauseaGastrointestinal disorders | 1/14 | 0/14 | 0/8 | 0/8 |
| AstheniaGeneral disorders | 1/14 | 1/14 | 0/8 | 0/8 |
| Ligament sprainInjury, poisoning and procedural complications | 0/14 | 1/14 | 0/8 | 0/8 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/14 | 1/14 | 0/8 | 0/8 |
| Age, Continuous(years) | Moxifloxacin | DAV132 + Moxifloxacin | DAV132 | Negative Control | Total |
|---|---|---|---|---|---|
| Mean | 35.4 ± 10.4 | 38.6 ± 12.1 | 27.9 ± 9.1 | 36.7 ± 11.8 | 35.3 ± 11.3 |
| Sex: Female, Male(Participants) | Moxifloxacin | DAV132 + Moxifloxacin | DAV132 | Negative Control | Total |
|---|---|---|---|---|---|
| Female | 9 | 10 | 4 | 5 | 28 |
| Male | 5 | 4 | 4 | 3 | 16 |
| Region of Enrollment(Participants) | Moxifloxacin | DAV132 + Moxifloxacin | DAV132 | Negative Control | Total |
|---|---|---|---|---|---|
| France | 14 | 14 | 8 | 8 | 44 |
| Body Mass Index (BMI) at screening visit(kg/m^2) | Moxifloxacin | DAV132 + Moxifloxacin | DAV132 | Negative Control | Total |
|---|---|---|---|---|---|
| Mean | 24.1 ± 3.3 | 24.9 ± 3.2 | 23.6 ± 3.2 | 23.3 ± 2.0 | 24.1 ± 3.0 |
The record gives a start of Mar 2014, a primary completion of Oct 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2020, 5 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Moxifloxacin
Da Volterra